for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Biogen Inc

BIIB.O

Latest Trade

219.39USD

Change

-2.92(-1.31%)

Volume

1,106,752

Today's Range

218.23

 - 

226.88

52 Week Range

214.88

 - 

468.55

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
222.31
Open
223.14
Volume
1,106,752
3M AVG Volume
33.04
Today's High
226.88
Today's Low
218.23
52 Week High
468.55
52 Week Low
214.88
Shares Out (MIL)
146.89
Market Cap (MIL)
32,655.72
Forward P/E
11.72
Dividend (Yield %)
--

Next Event

Q4 2021 Biogen Inc Earnings Call

Latest Developments

More

Biogen - To Continue To Urge CMS To Align Medicare Coverage For Class Of Amyloid-Directed Therapies With Populations Studied In Respective Clinical Trials, For Appropriate Use

U.S. Government Medicare Program Plans To Cover Alzheimer's Treatments Including Biogen's Aduhelm With Conditions

Medicare Plans To Restrict Access To Controversial, Pricey Alzheimer's Drug Aduhelm To Patients In Clinical Trials- Stat News

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Biogen Inc

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company's marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; GAZYVA indicated for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS), and other anti-CD20 therapies. The Company's pipeline includes BIIB074; BAN2401; BIIB061; BIIB067, BIIB124, BIIB074, BIIB118 and TMS-007.

Industry

Biotechnology & Drugs

Contact Info

225 Binney St

CAMBRIDGE, MA

02142-1031

United States

+1.781.4642000

https://www.biogen.com/

Executive Leadership

Stelios B. Papadopoulos

Independent Chairman of the Board

Michel Vounatsos

Chief Executive Officer, Director

Michael R. McDonnell

Chief Financial Officer, Executive Vice President

Ginger Gregory

Chief Human Resource Officer, Executive Vice President

Susan H. Alexander

Executive Vice President, Chief Legal Officer and Secretary

Key Stats

2.42 mean rating - 36 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

13.5K

2019

14.4K

2020

13.4K

2021(E)

10.9K
EPS (USD)

2018

26.200

2019

33.570

2020

33.700

2021(E)

19.167
Price To Earnings (TTM)
21.75
Price To Sales (TTM)
2.94
Price To Book (MRQ)
3.13
Price To Cash Flow (TTM)
12.89
Total Debt To Equity (MRQ)
69.71
LT Debt To Equity (MRQ)
60.14
Return on Investment (TTM)
10.28
Return on Equity (TTM)
8.50

Latest News

Latest News

Biogen eyes potential acquisitions - Stat News

Biogen Inc is working with investment bank Goldman Sachs to find potential targets for acquisitions, Stat News reported on Thursday, citing an unnamed source.

Biogen shares slide as Medicare proposal restricts coverage of Alzheimer's treatments

The U.S. Medicare program's proposal to severely limit coverage of new Alzheimer's treatments including Biogen's Aduhelm threatens to hurt sales of the controversial drug and dim prospects for similar medicines in development by other companies.

Biogen slumps after Medicare's restrictive decision on Alzheimer's drug

Shares of Biogen Inc fell nearly 10% on Wednesday after the U.S. government announced limited coverage of Alzheimer's treatments including the drugmaker's Aduhelm, dealing a blow to the controversial treatment that was approved last year.

BRIEF-Biogen - To Continue To Urge CMS To Align Medicare Coverage For Class Of Amyloid-Directed Therapies With Populations Studied In Respective Clinical Trials, For Appropriate Use

* BIOGEN - TO CONTINUE TO URGE CMS TO ALIGN MEDICARE COVERAGE FOR CLASS OF AMYLOID-DIRECTED THERAPIES WITH POPULATIONS STUDIED IN RESPECTIVE CLINICAL TRIALS, FOR APPROPRIATE USE

U.S. Medicare plans to cover Biogen Alzheimer's drug only for trial patients

The U.S. government Medicare program on Tuesday said it plans to cover Alzheimer's treatments including Biogen Inc's Aduhelm but will require patients to be enrolled in a clinical trial, limiting access to the treatment more than many expected.

U.S. Medicare program plans to cover Biogen's Aduhelm, with some conditions

The U.S. government's Medicare program on Tuesday said it plans to cover Alzheimer's treatments including Biogen Inc's Aduhelm, with some conditions.

Future of Biogen's Aduhelm hinges on U.S. Medicare Alzheimer's coverage

The future of Aduhelm, Biogen Inc's controversial and expensive Alzheimer's drug, may hinge on a decision due this week from the U.S. Medicare program on whether it will pay for the treatment.

Medicare asked to reassess 2022 premium hikes after Aduhelm price cut

U.S. Secretary of Health and Human Services Xavier Becerra on Monday asked the country's Medicare program to reassess its 2022 premium hikes, weeks after Biogen Inc cut the price of its Alzheimer's drug by about half.

Samsung BioLogics says report on Biogen deal talks untrue

Samsung BioLogics on Thursday denied a media report that said the South Korean firm was in talks to buy U.S. drugmaker Biogen Inc.

Samsung BioLogics denies report saying Samsung in talks to acquire Biogen

Samsung BioLogics said in a regulatory filing on Thursday that a report saying Samsung Group is in talks to acquire U.S. drugmaker Biogen Inc is not true.

Samsung Group in talks to buy Biogen - Korea Economic Daily

South Korea's Samsung Group is in talks to buy drugmaker Biogen Inc, the Korea Economic Daily reported https://www.kedglobal.com/newsView/ked202112290011?lang=us on Wednesday, citing investment banking sources.

Biogen, Eisai Alzheimer's drug lecanemab gets 'fast track' designation from FDA

Biogen Inc and Japanese partner Eisai Co said on Thursday the U.S. Food and Drug Administration (FDA) had granted "fast track" designation to their experimental therapy lecanemab for the treatment of early Alzheimer's disease.

Eisai-Biogen Alzheimer's drug difficult to assess-Japan ministry

A Japanese health ministry panel said on Wednesday that inconsistent trial results made it difficult to determine the efficacy of an Alzheimer's treatment developed by Eisai Co and Biogen Inc.

Biogen halves price of Alzheimer's drug to $28,200

Biogen Inc on Monday cut the price of its Alzheimer's drug by about half to $28,200 for an average weight person after facing slower-than-expected U.S. sales on complaints from hospitals that its high cost was not worth its benefits.

Biogen to cut U.S. price of Alzheimer's drug by 50%

Biogen Inc said on Monday it would reduce the price of its Alzheimer's disease drug by about 50%, representing a yearly cost of $28,200 per patient. (Reporting by Manas Mishra in Bengaluru; Editing by Anil D'Silva)

EU regulator rejects Biogen's Alzheimer's drug

The European Union's drug regulator on Friday rejected Biogen Inc's controversial Alzheimer's drug, Aduhelm, dealing a blow to the U.S. drugmaker after a panel voted against the treatment last month.

EU regulator not in favour of approving Biogen's Alzheimer's drug

The European Union's drug regulator said on Friday it had recommended against approving Biogen Inc's Alzheimer's drug, Aduhelm, dealing a blow to the U.S. drugmaker after a panel voted against the treatment last month.

Biogen plans to submit final design of Aduhelm confirmatory trial to FDA in March

Biogen Inc said on Thursday it was expecting to submit a final design for a post-marketing confirmatory study of its newly approved Alzheimer's drug, Aduhelm, to the U.S. Food and Drug Administration in March, and begin screening of patients in May.

Biogen's Alzheimer's drug gets negative European panel vote

A European Medicines Agency panel voted against approval of Biogen Inc's Alzheimer's drug Aduhelm, in another blow to prospects for a treatment already grappling with a slow rollout in the United States.

Biogen's Alzheimer's drug gets negative vote from EMA panel

Biogen Inc said on Wednesday the European Medicines Agency's panel had given a negative trend vote against the marketing application for its Alzheimer's disease drug. (Reporting by Manas Mishra in Bengaluru; Editing by Krishna Chandra Eluri)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up